在寻找未来抗菌药物时，以毒力而非生存能力为靶点。
Targeting virulence not viability in the search for future antibacterials.
作者信息
Heras Begoña, Scanlon Martin J, Martin Jennifer L
机构信息
La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Vic.
出版信息
Br J Clin Pharmacol. 2015 Feb;79(2):208-15. doi: 10.1111/bcp.12356.
Abstract
New antibacterials need new approaches to overcome the problem of rapid antibiotic resistance. Here we review the development of potential new antibacterial drugs that do not kill bacteria or inhibit their growth, but combat disease instead by targeting bacterial virulence.
摘要
新型抗菌药物需要新的方法来克服抗生素耐药性迅速产生的问题。在此，我们综述了潜在新型抗菌药物的研发情况，这些药物并非杀死细菌或抑制其生长，而是通过靶向细菌毒力来对抗疾病。
相似文献
1
Targeting virulence not viability in the search for future antibacterials.
Br J Clin Pharmacol. 2015 Feb;79(2):208-15. doi: 10.1111/bcp.12356.
2
Antivirulence compounds: a future direction to overcome antibiotic resistance?
Future Microbiol. 2020 Mar;15:299-301. doi: 10.2217/fmb-2019-0294.
3
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.
Nat Rev Drug Discov. 2017 Jul;16(7):457-471. doi: 10.1038/nrd.2017.23. Epub 2017 Mar 24.
4
Novel agents to inhibit microbial virulence and pathogenicity.
Expert Opin Ther Pat. 2010 Oct;20(10):1401-18. doi: 10.1517/13543776.2010.511176.
5
The biology and future prospects of antivirulence therapies.
Nat Rev Microbiol. 2008 Jan;6(1):17-27. doi: 10.1038/nrmicro1818.
6
Anti-virulence strategies to combat bacteria-mediated disease.
Nat Rev Drug Discov. 2010 Feb;9(2):117-28. doi: 10.1038/nrd3013. Epub 2010 Jan 18.
7
Quorum quenching agents: resources for antivirulence therapy.
Mar Drugs. 2014 May 30;12(6):3245-82. doi: 10.3390/md12063245.
8
Quenching the quorum sensing system: potential antibacterial drug targets.
Crit Rev Microbiol. 2011 May;37(2):121-40. doi: 10.3109/1040841X.2010.532479. Epub 2011 Jan 27.
9
Multi-targeting by monotherapeutic antibacterials.
Nat Rev Drug Discov. 2007 Jan;6(1):41-55. doi: 10.1038/nrd2202.
10
The millennium bugs--the need for and development of new antibacterials.
Int J Antimicrob Agents. 2000 Sep;16(1):51-9. doi: 10.1016/s0924-8579(00)00189-8.
引用本文的文献
1
Novel inhibition of sortase A by plantamajoside: implications for controlling multidrug-resistant infections.
Appl Environ Microbiol. 2025 Jan 31;91(1):e0180424. doi: 10.1128/aem.01804-24. Epub 2024 Dec 31.
2
Screening of Novel Drug Targets and Drug Design for : A Subtractive Proteomics Approach.
Curr Res Microb Sci. 2024 Oct 19;7:100291. doi: 10.1016/j.crmicr.2024.100291. eCollection 2024.
3
Periodontitis: etiology, conventional treatments, and emerging bacteriophage and predatory bacteria therapies.
Front Microbiol. 2024 Sep 26;15:1469414. doi: 10.3389/fmicb.2024.1469414. eCollection 2024.
4
Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae.
Drug Deliv Transl Res. 2025 May;15(5):1739-1754. doi: 10.1007/s13346-024-01708-5. Epub 2024 Sep 16.
5
Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a "High Value" Vaccine Candidate Specific for Treating Multi-Strain Infections.
Toxins (Basel). 2024 Jun 14;16(6):271. doi: 10.3390/toxins16060271.
6
Crippling of Klebsiella pneumoniae virulence by metformin, N-acetylcysteine and secnidazole.
BMC Microbiol. 2023 Aug 22;23(1):229. doi: 10.1186/s12866-023-02969-9.
7
Antibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosis.
bioRxiv. 2025 Jun 2:2023.08.02.551661. doi: 10.1101/2023.08.02.551661.
8
Potent antifungal properties of gallic acid in against .
BioTechnologia (Pozn). 2023 Jun 26;104(2):105-119. doi: 10.5114/bta.2023.127202. eCollection 2023.
9
The natural product, echinatin, protects mice from methicillin-resistant pneumonia by inhibition of alpha-hemolysin expression.
Front Microbiol. 2023 Apr 14;14:1128144. doi: 10.3389/fmicb.2023.1128144. eCollection 2023.
10
A Buried Water Network Modulates the Activity of the Disulphide Catalyst DsbA.
Antioxidants (Basel). 2023 Feb 4;12(2):380. doi: 10.3390/antiox12020380.
本文引用的文献
1
Development of quorum-based anti-virulence therapeutics targeting Gram-negative bacterial pathogens.
Int J Mol Sci. 2013 Aug 9;14(8):16570-99. doi: 10.3390/ijms140816570.
2
Disarming Burkholderia pseudomallei: structural and functional characterization of a disulfide oxidoreductase (DsbA) required for virulence in vivo.
Antioxid Redox Signal. 2014 Feb 1;20(4):606-17. doi: 10.1089/ars.2013.5375. Epub 2013 Sep 20.
3
Quo vadis quorum quenching?
Curr Opin Pharmacol. 2013 Oct;13(5):688-98. doi: 10.1016/j.coph.2013.07.003. Epub 2013 Jul 19.
4
Curcumin inhibits the Sortase A activity of the Streptococcus mutans UA159.
Appl Biochem Biotechnol. 2013 Sep;171(2):396-402. doi: 10.1007/s12010-013-0378-9. Epub 2013 Jul 11.
5
Curcumin reduces Streptococcus mutans biofilm formation by inhibiting sortase A activity.
Arch Oral Biol. 2013 Oct;58(10):1343-8. doi: 10.1016/j.archoralbio.2013.05.004. Epub 2013 Jun 16.
6
Pilicides inhibit the FGL chaperone/usher assisted biogenesis of the Dr fimbrial polyadhesin from uropathogenic Escherichia coli.
BMC Microbiol. 2013 Jun 12;13:131. doi: 10.1186/1471-2180-13-131.
7
A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.
J Infect Dis. 2013 Sep;208(6):921-8. doi: 10.1093/infdis/jit245. Epub 2013 Jun 3.
8
Interference of bacterial cell-to-cell communication: a new concept of antimicrobial chemotherapy breaks antibiotic resistance.
Front Microbiol. 2013 May 13;4:114. doi: 10.3389/fmicb.2013.00114. eCollection 2013.
9
Discovery of Staphylococcus aureus sortase A inhibitors using virtual screening and the relaxed complex scheme.
Chem Biol Drug Des. 2013 Oct;82(4):418-28. doi: 10.1111/cbdd.12167.
10
Resistance to the quorum-quenching compounds brominated furanone C-30 and 5-fluorouracil in Pseudomonas aeruginosa clinical isolates.
Pathog Dis. 2013 Jun;68(1):8-11. doi: 10.1111/2049-632X.12039. Epub 2013 Apr 17.
Zotero 插件